Erchonia Corporation, the global leader in low level laser healthcare applications, announces results of a pilot study testing the ability of low level lasers to reduce the negative side-effects of radiation therapy for cancer patients.

Patients who undergo aggressive cancer therapies must also endure a host of painful side-effects. An estimated 80% suffer from severe toxicity with nearly 50% experiencing side-effects so intense they choose to terminate their cancer treatment before completion.

The pilot investigation assessed the efficacy of an Erchonia low-level laser to combat these adverse reactions. All patients who received the laser treatment revealed a significant improvement in pain, dermatitis and oral mucositis caused by radiation therapy.

Dr. David Bryant, an oncologist at the Via Christi Medical Center in Kansas, performed the study and used the Erchonia laser device to treat cancer patients who were experiencing a significant amount of pain. After a few treatments with the laser, patients ready to abandon radiation were able to complete their regimen in full.

Dr. Bryant remarks, "The study was designed to show a reduction in pain, improved treatment retention, and reduction in treatment toxicity. It was incredible to see such a significant reduction in negative side effects. The resolution of these symptoms could be the difference between cancer treatment success and failure."

Based on the results of this study, Erchonia has embarked on a clinical trial to conclude in 2011 and plans to pursue FDA clearance in 2012.

"The goal is to prove to physicians and patients that a safe and effective treatment is available to suppress the common but severe adverse events of radiation therapy," says Steve Shanks, president of Erchonia. "We need to give every cancer patient the best possible chance to succeed."

Source:
Erchonia Corporation